OncoSec Medical to Present at Two Conferences in New York City in April

Company to Present at 13th Annual Needham Healthcare Conference and HemOnc Today Melanoma and Cutaneous Malignancies Meeting

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April.

Punit Dhillon, President and CEO, will present a corporate overview of the company at the 13th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, April 8th, at 11:20 a.m. ET. That presentation will be webcast live, and available at the following link: http://wsw.com/webcast/needham65/oncs

OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available for 90 days in the “Events” section of the OncoSec web page at http://www.oncosec.com

Additionally, Adil Daud, M.D., Principal Investigator for OncoSec’s Phase 2 melanoma study, will discuss developing intralesional therapies at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the Sheraton New York Times Square Hotel, in New York City on Friday, April 11th, at 2:40 p.m. ET.

HemOnc Today will bring together more than 25 renowned speakers and 200 colleagues to participate in an intimate and interactive meeting during the weekend of April 11-12, 2014, in New York City, New York. The dynamic meeting program is designed to encourage open communications and exchange of ideas among leading hematologists, oncologists, dermatologists, researchers, physician assistants, nurses, and students. For more information, please visit: http://www.healio.com/meeting/hemonctodaymelanoma/home

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials in patients with metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapy approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:
OncoSec Medical Inc.
Veronica Vallejo, CFO

Source: OncoSec Medical Inc.